Project ALS is pleased to share that the FDA has approved the drug edaravone – the first approved ALS treatment in over 20 years.
Edaravone, a free radical scavenger, appears to react with nerve-damaging compounds generated as part of the disease process. After six months of treatment, on top of standard-of-care, data showed the intravenous drug reduced the rate of functional decline in patients by about a third.
Read more
Holiday Town Hall: 2025 Research Goals
WATCH OUR LATEST VIRTUAL TOWN HALL Watch the Project ALS Holiday Town Hall: 2025 Research Goals, where we discussed our 2025 research goals including innovative
December 12, 2024
No Comments
